
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Clemizole hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Recipient : Epygenix Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Epygenix Therapeutics Initiates Phase 2 Study for Dravet Syndrome With EPX-100
Details : This Phase 2 study will confirm the efficacy and safety of EPX-100 with children suffering from Dravet Syndrome. The Company is now recruiting patients for this clinical study, collaborated with GreenLight Clinical.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 17, 2020
Lead Product(s) : Clemizole hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Recipient : Epygenix Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
